

Dymista®

Marketing Plan 2015

Dymista

drug of choice
for allergic rhinitis

MEDA



CIP2093
Argentum Pharmaceuticals LLC v. Cipla Ltd.
IPR2017-00807

HIGHLY CONFIDENTIAL -
SUBJECT TO STIPULATED PROTECTIVE ORDER

MEDA_APTX03501812

Marketing Plan 2015

Product	Dymista
Generic Name	(azelastine hydrochloride and fluticasone propionate) Nasal Spray 137 mcg/50 mcg per spray
Launch	September 24, 2012
Country	United States
Business Unit	Marketing
Product Manager	Jeff Germani
Medical Manager	Nancy Ruiz, MD
Product Team	Stuart Loesch, Meghan Hausner and Katie Weibarth

MEDA

- 2 -

Dymista

HIGHLY CONFIDENTIAL -
SUBJECT TO STIPULATED PROTECTIVE ORDER

MEDA_APTX03501813

Content

- Product Profile
- Disease State
- Market Dynamics
- Competitive Environment
- Product Dynamics
- SWOT Analysis
- Key Issues/Strategic Planning
- Sales Force
- Tactical Planning
- Financials

MEDA

- 3 -

Dymista

HIGHLY CONFIDENTIAL -
SUBJECT TO STIPULATED PROTECTIVE ORDER

3

MEDA_APTX03501814

Product Profile

- **Trade Name:** Dymista (azelastine hydrochloride and fluticasone propionate) Nasal Spray 137mcg/50mcg per Spray
- **Launch Date:** September 24, 2012
- **Patent Protection:** 2026
- **Substance Class:** Nasal Spray
- **Active Ingredients:** azelastine hydrochloride/fluticasone propionate
- **Indication:** Seasonal Allergic Rhinitis (SAR) for patients 12 years and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief
- **Dosage:** 1 spray/nostril 2x daily
- **Pack size:** 23 grams net fill (120 metered sprays)
- **Prices:** \$145.95 (wholesale acquisition cost); \$82.20 (net price); most patients pay as little as \$14 with the copay card or receive \$100 off their cash price
- **Reimbursement status: Percent of Lives Covered by Status**

	<u>2015</u>
Preferred	32% ¹
Covered (Unrestricted Tier 3)	26%
Restricted (PA/SE)	12%
Not Covered	30%

PA= Prior Authorization

SE= Step Edit

¹First half of 2015 prior to Nasonex generic

²Not listed refers to a database limitation; assume Tier 3

MEDA

- 4 -

Dymista

HIGHLY CONFIDENTIAL -
SUBJECT TO STIPULATED PROTECTIVE ORDER

4

MEDA_APTX03501815

Dymista

Disease State

drug of choice
for allergic rhinitis

MEDA

- 5 -

HIGHLY CONFIDENTIAL -
SUBJECT TO STIPULATED PROTECTIVE ORDER

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.